Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 43, Issue 3, 1997, Pages 193-200

  Ingle, James N ^a   Kardinal, Carl G ^b   Suman, Vera J ^a   Veeder, Michael H ^c   Schaefer, Paul L ^d   Kirschling, Ronnie J ^e   Mailliard, James A ^f  

^a MAYO CLINIC   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

^c Illinois Oncol Res Assoc CCOP   (United States)

^d Toledo CCOP   (United States)

^e Duluth CCOP   (United States)

^f CREIGHTON UNIVERSITY   (United States)

Author keywords

5 Fluorouracil; Breast cancer; Chemotherapy; CSFs; Filgrastim; Leucovorin; Metastatic; Mitoxantrone

Indexed keywords

DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; MAXIMUM PERMISSIBLE DOSE; MUSCULOSKELETAL DISEASE; NAUSEA; PRIORITY JOURNAL; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FILGRASTIM; FLUOROURACIL; HUMANS; LEUCOVORIN; LEUKOPENIA; MIDDLE AGED; MITOXANTRONE; NEOPLASM METASTASIS; PATIENT SELECTION; PLATELET COUNT; SURVIVAL RATE; THROMBOCYTOPENIA; TIME FACTORS;

EID: 0030959905     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005749115033     Document Type: Article

References (19)

1. Triozzi PL, Rhoades C, Thornton DE: High-dose chemotherapy for breast cancer. Cancer Treat Rev 21: 185-198, 1995
2. Schiffer LM, Braunschweiger PG, Stragand JJ, Poulakos L: The cell kinetics of human mammary cancers. Cancer 43: 1707-1719, 1979
3. Saletan S: Mitoxantrone: An active, new antitumor agent with an improved therapeutic index. Cancer Treat Rev 14: 297-303, 1987
4. Traganos F, Evenson DP, Staiano-Coico L, Darzynkiewicz Z, Melamed MR: Action of dihydroxyanthraquinone on cell cycle progression and survival of a variety of cultured mammalian cells. Cancer Res 40: 671-681, 1980
5. LeMaistre CF, Herzig R: Mitoxantrone: Potential for use in intensive therapy. Semin Oncol 17 (suppl 3): 43-48, 1990
6. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560-571, 1989
7. Cowan JD, Neidhart J, McClure S, Coltman CA Jr, Gumbart C, Martino S, Hutchins LF, Stephens RL, Vaughan CB, Osborne CK: Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: A Southwest Oncology Group Study. J Natl Cancer Inst 83: 1077-1084, 1991
8. Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K: Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 3: 123-132, 1985
9. Hainsworth JD, Andrews MB, Johnson DH, Greco FA: Mitoxantrone, fluorouracil, and high dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. J Clin Oncol 9: 1731-1736, 1991
10. Jones SE, Mennel RG, Brooks B, Westrick MA, Allison MA, Paulson RS, Tilmann K, Rea B: Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. J Clin Oncol 9: 1736-1739, 1991
11. Wils JA: Mitoxantrone, leucovorin and high-dose infusional 5-fluorouracil: An effective and well-tolerated regimen for the treatment of advanced breast cancer. Eur J Cancer 29A: 2106-2108, 1993
12. Swain SM, Honig SF: Mitoxantrone, 5-FU, and leucovorin in breast cancer. Med Ped Oncol 22: 370-374, 1994
13. Mammoliti S, Merlini L, Caroti C, Gallo L: Mitoxantrone, 5-fluorouracil and levo-leucovorin as salvage treatment in advanced breast cancer patients. Eur J Cancer 30A: 248-249, 1994
14. Jolivet J, Belanger K, Yelle L, Guevin R, Potvin M, Wilson J, Rudinskas L, Latreille J, Dionne J, Gagne L, Ayoub J: The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer. Eur J Cancer 30A: 626-628, 1994
15. Repetto L, Miglietta L, Gardin G, Lanfranco C, Naso C, Merlini L, Giudici S, Verturino A, Campora E, Testore F, Rosso R: Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer. Breast Cancer Res Treat 30: 133-137, 1994
16. Ingle JN, Kuross SA, Mailliard JA, Loprinzi CL, Jung SH, Nelimark RA, Krook JE, Long HJ: Evaluation of piroxantrone in women with metastatic breast cancer and failure on nonanthracycline chemotherapy. Cancer 74: 1733-1738, 1994
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
18. Lemmens J, Berteloot P, Thomas J, Wildiers J, Paridaens R: Mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer. Eur J Cancer 31A: 2114-2115, 1995
19. Gebbia V, Valenza R, Testa A, Cannata G, Verderame F, Gebbia N: Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer. Eur J Cancer 30A: 1734-1736, 1994